discover, derisk and develop
Accelerate transformation of biologics into drugs with strategic insights
We turn your research programs into therapies for patients with high unmet needs.
We turn your research programs into therapies for patients with high unmet needs.
Guide antigen/linker (cleavable/non-cleavable)/payload (auristatins/ topoisomerase or novel) selection, antibody/protein optimization, conjugation strategies, and ADC generation for mono- and bispecific formats. Direct preclinical pharmacology design and development candidate prioritization to maximize clinical success.
Precise antigen selection and design of developable bispecific/biparatopic formats (common light chain, tandem VHH, appended IgG, scFv-based) featuring AND/OR gating, Fc engineering, and expanded MoAs including T-cell engagers, dual targeting, and blood-brain barrier delivery.
Expert guidance on in vivo (mouse/rabbit/llama/transgenic) and in vitro (phage/yeast display) discovery campaigns across scFv/Fab/VHH formats for epitope-specific, conditional, pH-dependent, and developable antibodies. Specialized in Fc engineering, humanization (mouse/llama/rabbit), and affinity optimization to ensure manufacturability and clinical viability.
Align scientific strategy across scientific advisory boards, boards of directors, and external stakeholders, ensuring clear, evidence-based decision-making. Provide technical due diligence for partnerships and investments, supported by competitive intelligence across biologics platforms and disease areas. Shape IP portfolios by refining claim strategy, identifying key datasets for patent term extension, and supporting declarations and expert witnessing in patent litigation.
Streamline R&D programs through process optimization, global CRO oversight, and team/infrastructure scaling to accelerate IND-ready assets with high clinical success potential. Proven expertise establishing multiple discovery labs in startup/incubator environments, optimizing workflows and team composition, and leveraging vendor networks for rapid R&D readiness.
Build high-performing teams through expert people management, 1:1 coaching for leaders and managers, and targeted mentoring. Accelerate academic-to-industry transitions, foster resilient low-turnover cultures, and develop future leaders. Closely partner with HR teams in developing policies and processes aligned with R&D and company wide goals.
Summary of specific hands-on experience and services (pdf)
DownloadWe offer hourly consulting, retainer packages (10–40+ hours/month) and fractional C-level executive roles. Open to project-based work, SAB/BoD participation, technical report generation/editing, and strategic advisory support. Extensive network referrals for CMC, clinical, HR, and finance needs available.

Our Founder, Nimish Gera is a biotech executive with broad experience across antibody-based modalities including mono- and bispecific antibodies, protein fusions, and antibody-drug conjugates (ADCs) across several therapeutic areas such as oncology, immunology, autoimmune, and rare diseases. He has held scientific and/or leadership roles at companies ranging from early-stage startups like Mythic Therapeutics and Oncobiologics to large organizations such as Alexion Pharmaceuticals and Genentech. With more than fifteen years in drug development, Nimish has successfully advanced complex bispecific and ADC programs from concept through preclinical and early clinical stages. Nimish has a proven track record of bringing multiple drug candidates to clinical trials, publishing peer-reviewed articles, building IP portfolios, and chairing national and international meetings on antibody therapeutics. He serves as Associate Editor of the journal mAbs, hosts the Chain Protein Engineering podcast, and teaches the Developability of Bispecific Antibodies short course at the PEGS Boston and Europe conferences. He holds a PhD in Chemical and Biomolecular Engineering from North Carolina State University and a B.Tech in Chemical Engineering from the Indian Institute of Technology, Guwahati.

Discover an excellent collection of podcasts on ADCs, bispecifics, developability, AI, patent landscape and licensing with our founder, Nimish Gera as the host on The Chain: Protein Engineering Podcast.
Nimish Gera has been involved with mAbs since 2019 serving as an Assistant Editor from 2019-2024 and an Associate Editor since 2025. mAbs is a multidisciplinary, open access journal dedicated to the art and science of antibody research and development.
A highly popular course on Developability of Bispecific Antibodies is offered at PEGS Boston and PEGS Europe taught independently by Nimish Gera with real case studies and extensive background material.
A list of our publications can be found on Google Scholar. We are open to collaborating on original research and review articles, please contact via the contact form above if interested.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.